Temozolomide in aggressive pituitary adenomas and carcinomas. - Wikidata - wikimedia - TriplyDB

Temozolomide in aggressive pituitary adenomas and carcinomas.

Temozolomide in aggressive pituitary adenomas and carcinomas.

http://www.wikidata.org/entity/Q38010032

about

Systemic therapy of Cushing's syndrome Treatment of pituitary carcinomas and atypical pituitary adenomas: a review Invasive adenoma and pituitary carcinoma: a SEER database analysis A differential diagnosis of inherited endocrine tumors and their tumor counterparts New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy The place of medical treatment of acromegaly: current status and perspectives.Targeted therapy with kinase inhibitors in aggressive endocrine tumors.Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.Aggressive tumors and difficult choices in acromegaly.Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation.Aggressive pituitary adenomas--diagnosis and emerging treatments.Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature.Emerging drugs for Cushing's disease.Temozolomide-Induced Shrinkage of Invasive Pituitary Adenoma in Patient with Nelson's Syndrome: A Case Report and Review of the Literature.Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.The safety of treatments for prolactinomas.How effective is temozolomide for treating pituitary tumours and when should it be used?Pituitary Carcinoma in a Patient with an SDHB Mutation.Ascochlorin Suppresses MMP-2-Mediated Migration and Invasion by Targeting FAK and JAK-STAT Signaling Cascades.Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.Pituitary-Directed Therapies for Cushing's Disease.

P2860

Q22000607-CE828811-3DFB-443E-980D-0B82D1B760EC Q30872897-228E2447-32F9-4846-A71F-846C388DCAED Q35067759-CAC1A11C-464F-4843-97E0-82CDBEB5021F Q37023603-7309D942-C777-4B8E-B122-299483FA927A Q37049132-70FB3AF8-D9E5-4CCF-A352-7971C9E3DE6C Q38100275-74940A7A-25A3-4380-AF18-EEA2968A89F6 Q38107011-71F06247-719C-4037-BC76-DC22822E46F6 Q38129776-620A2DCD-9CD1-4117-93C3-62848C8DEB82 Q38167711-D1D9FD68-1A8C-4A06-9E1B-26D0F9B3870A Q38169995-06C27E68-A2A3-4E4A-BB33-6CFB1A459A74 Q38211375-CD6770B2-D3A5-4FCD-BC60-7F455D8F27CE Q38365297-63987759-F659-4FC6-8CB0-C4115927A9F0 Q38505947-47C276E1-3872-4FE6-90B9-6FF5512C4D97 Q38556703-987C2F50-BDC5-4EEC-868F-B24E596C4675 Q38650974-E537C317-4FEC-47E8-8452-655AE8AF49AF Q38726058-898431B3-A559-4694-A5EC-31866C226735 Q38825694-A6B4FA1A-F92E-414A-A4BF-6C66A61D8BE8 Q45805389-D849F4F7-3238-4602-96F6-B77DFEC58AF1 Q48345101-64CAE9AE-2CC6-48CC-A055-F913948F2B05 Q53629828-2F6C8EF3-A441-49FA-A778-116E63842996 Q54961209-E8543612-79BE-4E12-BAE5-FEBDC2A63462

P2860

Temozolomide in aggressive pituitary adenomas and carcinomas.

http://www.wikidata.org/entity/Q38010032

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Temozolomide in aggressive pituitary adenomas and carcinomas.

@en

type

label

Temozolomide in aggressive pituitary adenomas and carcinomas.

@en

prefLabel

Temozolomide in aggressive pituitary adenomas and carcinomas.

@en

P1433

Q38010032-69CCCC8D-798F-4A28-A05C-F78DF7E9B63E

P1476

Q38010032-16FED571-A182-492F-856B-2C45DECF63C8

P2093

Q38010032-1DA15E82-0DEB-4DE9-99F6-AEE28A20C1C6

Q38010032-47FFB140-548C-4CF6-85B6-AD3A25B18B6D

Q38010032-4C20A605-4B13-4EB1-BBE1-B6F0FA6F2FBD

Q38010032-5F7EF2A4-3549-45A4-B090-2AB4D051E999

Q38010032-6EE99E12-8010-42BB-9DAE-F37C99F3EBFB

Q38010032-7A12D0C3-7C2B-4EE0-A2D1-ABD324322CF0

Q38010032-C2464C5C-8920-45A2-8F98-214C9355697D

P275

Q38010032-90279DF8-53A4-4AC9-8B4E-E5147A08B7BF

P2860

Q38010032-049BBB34-B246-4CD0-A59A-D4C9B77DC138

Q38010032-1AC31B0C-629D-4085-8E8E-C16B28D668E0

Q38010032-1C38DF79-8AFC-4B9E-9F00-4092B4943938

Q38010032-1D72FA16-3E49-4FCB-B88E-FC60A8B476FC

Q38010032-226EEE86-2C33-4582-A089-CC7B279E0B3C

Q38010032-234E3303-AAFF-42FE-9167-88F2AD368A01

Q38010032-304E3AC6-54A6-4295-A86F-29B2699955A8

Q38010032-324E46E6-A8F8-44AD-83F3-007B71B0DAA9

Q38010032-34BF30F8-5240-4ED8-95F6-5139F5028118

Q38010032-41DC6285-4055-45F5-BE73-90BF286A9F6E

P304

Q38010032-B51DF55F-47DB-4F93-B1BD-2904CC74038D

P31

Q38010032-DC1C0FA5-3AE6-4104-A986-83C3C45FD8D3

P356

Q38010032-CFE28A06-15AD-4873-BAAE-75E63600EC69

P478

Q38010032-5E11CFCF-D384-4C6B-B527-06C118E86C88

P50

Q38010032-51049F2B-62A5-431F-BC40-597EA6B8B663

P5008

Q38010032-143E7020-D473-4BCA-A424-E0CCB57C21B0

P577

Q38010032-9CC8EEE1-7F5C-4F94-A893-DFCB81ABD76D

P698

Q38010032-49F1DFB9-9CF3-499F-8B3F-C3CC6DAC5823

P921

Q38010032-30DDA515-9510-4DCC-9F46-D676647E8C28

Q38010032-3B4878B2-5799-4785-8EDE-295D6CAFFD18

Q38010032-43E11030-466D-4E4C-9FD9-96347B2B3B1E

Q38010032-992EE8E9-0B82-4714-ADC4-D255BEB7DC96

Q38010032-E70FFC90-1F7D-4A9A-A170-C4AE5FCDE7EC

Q38010032-F6187ECE-0BCB-4FDC-9BCB-141DE5466906

P932

Q38010032-F5305397-7641-43E4-BE3B-BDC72AC5FF7F

P356

P1433

P1476

Temozolomide in aggressive pituitary adenomas and carcinomas

@en

P2093

Bernd W Scheithauer

http://www.w3.org/2001/XMLSchema#string

Camilo E Fadul

http://www.w3.org/2001/XMLSchema#string

Eva Horvath

http://www.w3.org/2001/XMLSchema#string

Fabio Rotondo

http://www.w3.org/2001/XMLSchema#string

Humberto Uribe

http://www.w3.org/2001/XMLSchema#string

Kalman Kovacs

http://www.w3.org/2001/XMLSchema#string

Leon D Ortiz

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 3.0 Unported

P2860

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression

Temozolomide for the treatment of metastatic melanoma: a systematic review.

Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.

Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.

Current and future developments in the use of temozolomide for the treatment of brain tumours.

Clinical relevance of MGMT in the treatment of cancer.

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

P304

119-123

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.6061/CLINICS/2012(SUP01)20

http://www.w3.org/2001/XMLSchema#string

P478

67 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22584716

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

pituitary neoplasm

pituitary adenoma

P932

3328813

http://www.w3.org/2001/XMLSchema#string